69 related articles for article (PubMed ID: 18021497)
1. Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.
Meadows ES; Rousculp M; Sasser AC; Birnbaum HG; Moyneur E; Mallet D; Johnston JA
Curr Med Res Opin; 2007 Dec; 23(12):3215-22. PubMed ID: 18021497
[TBL] [Abstract][Full Text] [Related]
2. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
3. Patient experience with a new teriparatide delivery device.
Dore RK; Feldman RG; Taylor KA; See K; Dalsky GP; Warner MR
Curr Med Res Opin; 2009 Oct; 25(10):2413-22. PubMed ID: 19656016
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
5. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
[TBL] [Abstract][Full Text] [Related]
6. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
7. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
8. Predicting pharmacy costs and other medical costs using diagnoses and drug claims.
Zhao Y; Ash AS; Ellis RP; Ayanian JZ; Pope GC; Bowen B; Weyuker L
Med Care; 2005 Jan; 43(1):34-43. PubMed ID: 15626932
[TBL] [Abstract][Full Text] [Related]
9. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
Losada BR; Zanchetta JR; Zerbini C; Molina JF; De la Peña P; Liu CC; Smith RB; Nino AJ; Krohn K; Warner MR
J Clin Densitom; 2009; 12(1):63-70. PubMed ID: 19028124
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of psoriasis compared to the general population and stratified by disease severity.
Yu AP; Tang J; Xie J; Wu EQ; Gupta SR; Bao Y; Mulani PM
Curr Med Res Opin; 2009 Oct; 25(10):2429-38. PubMed ID: 19663687
[TBL] [Abstract][Full Text] [Related]
11. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
12. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis pharmacotherapy and counseling services in US ambulatory care clinics: opportunities for multidisciplinary interventions.
Teschemaker A; Lee E; Xue Z; Wutoh AK
Am J Geriatr Pharmacother; 2008 Dec; 6(5):240-8. PubMed ID: 19161926
[TBL] [Abstract][Full Text] [Related]
14. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
15. Combined use of teriparatide and TNFalpha blockade: safety.
Migliore A; Massafra U; Capuano A; Martin SM
Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):18-20. PubMed ID: 18180602
[TBL] [Abstract][Full Text] [Related]
16. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
Toenders WG
Ned Tijdschr Geneeskd; 2006 Apr; 150(15):879; author reply 879. PubMed ID: 16676521
[No Abstract] [Full Text] [Related]
17. Treatment of osteoporosis with Teriparatide rhPTH(1-34).
San Martin J
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):406. PubMed ID: 15758281
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
19. Relation of bisphosphonate therapies and risk of developing atrial fibrillation.
Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD
Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739
[TBL] [Abstract][Full Text] [Related]
20. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
Foster SA; Foley KA; Meadows ES; Johnston JA; Wang SS; Pohl GM; Long SR
Osteoporos Int; 2011 Feb; 22(2):551-7. PubMed ID: 20798929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
